Loading...
Header Logo
Keywords
Last Name
Institution

Francesco Massari MD, PhD

TitleAssociate Professor
InstitutionUniversity of Massachusetts Medical School
DepartmentRadiology
AddressUniversity of Massachusetts Medical School
55 Lake Ave North
Worcester MA 01605
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentRadiology


    Collapse Biography 
    Collapse education and training
    Sapienza University of Rome, Rome, RM, ItalyMSRadiology
    Sapienza University of Rome, Rome, RM, ItalyMD
    Sapienza University of Rome, Rome, RM, ItalyPHDRadiology
    Medical University of South Carolina, Charleston, South CarolinaFellowship
    University of Massachusetts Medical School, Worcester, MAFellowship

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Aurilio G, Santoni M, Massari F, Cimadamore A, Rizzo A, Mollica V, Verri E, Battelli N, Montironi R. Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. Cancers (Basel). 2021 Oct 18; 13(20). PMID: 34680377.
      View in: PubMed
    2. Kuhn AL, Puri AS, Massari F, Singh J. Intravascular Wrap for Treatment of Basilar Artery Perforator Aneurysm. Cureus. 2021 Sep; 13(9):e18021. PMID: 34692271.
      View in: PubMed
    3. Rizzo A, Santoni M, Mollica V, Fiorentino M, Brandi G, Massari F. Microbiota and prostate cancer. Semin Cancer Biol. 2021 Sep 15. PMID: 34536504.
      View in: PubMed
    4. Rizzo A, Merler S, Sorgentoni G, Oderda M, Mollica V, Gadaleta-Caldarola G, Santoni M, Massari F. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. Expert Opin Drug Metab Toxicol. 2021 Aug 19. PMID: 34407702.
      View in: PubMed
    5. Marchetti A, Rosellini M, Rizzo A, Mollica V, Battelli N, Massari F, Santoni M. An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2021 Aug 18; 1-14. PMID: 34405738.
      View in: PubMed
    6. Rizzo A, Oderda M, Mollica V, Merler S, Morelli F, Fragomeno B, Taveri E, Sorgentoni G, Santoni M, Massari F. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. Anticancer Drugs. 2021 Aug 11. PMID: 34387593.
      View in: PubMed
    7. Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Target Oncol. 2021 Aug 02. PMID: 34338966.
      View in: PubMed
    8. Mollica V, Brocchi S, Dall'Olio FG, Marcolin L, Paccapelo A, Santoni M, Rizzo A, Montironi R, Golfieri R, Massari F, Ardizzoni A. Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers (Basel). 2021 Jul 12; 13(14). PMID: 34298702.
      View in: PubMed
    9. Massari F, Rizzo A, Mollica V, Rosellini M, Marchetti A, Ardizzoni A, Santoni M. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. Eur J Cancer. 2021 Jul 12; 154:120-127. PMID: 34265504.
      View in: PubMed
    10. Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Massari F, Santoni M, Scarpelli M, Cheng L, Montironi R. Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. Cancers (Basel). 2021 Jul 11; 13(14). PMID: 34298683.
      View in: PubMed
    11. Rizzo A, Mollica V, Santoni M, Massari F. Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. Expert Rev Gastroenterol Hepatol. 2021 Jul 01; 1-8. PMID: 34167420.
      View in: PubMed
    12. Elnazeir M, Nobel L, Narayanan S, Darmoch F, Massari F, Fitzgibbons T, Carandang RA, Jun-O'Connell A. Left Ventricular Noncompaction Cardiomyopathy as a Potential Cause of Bilateral Posterior Cerebral Artery Stroke - a Rare and Unique Clinical Occurrence. Am J Case Rep. 2021 Jun 22; 22:e931103. PMID: 34157014.
      View in: PubMed
    13. Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? Int J Mol Sci. 2021 Jun 09; 22(12). PMID: 34207825.
      View in: PubMed
    14. Basso U, Facchinetti A, Rossi E, Maruzzo M, Conteduca V, Aieta M, Massari F, Fraccon AP, Mucciarini C, Sava T, Santoni M, Pegoraro C, Durante E, Nicodemo M, Perin A, Bearz A, Gatti C, Fiduccia P, Diminutto A, Barile C, De Giorgi U, Zamarchi R, Zagonel V. Prognostic Role of Circulating Tumor Cells (CTCS) in Metastatic Renal Cell Carcinoma: A Large, Multicenter Prospective Trial. Oncologist. 2021 Jun 02. PMID: 34077597.
      View in: PubMed
    15. Santoni M, Rizzo A, Mollica V, Rosellini M, Marchetti A, Fragomeno B, Battelli N, Massari F. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun 01. PMID: 34058953.
      View in: PubMed
    16. Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi AB, Montironi R. Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. Int J Mol Sci. 2021 May 24; 22(11). PMID: 34073818.
      View in: PubMed
    17. Santoni M, Massari F, Montironi R, Battelli N. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. Biochim Biophys Acta Rev Cancer. 2021 Apr 29; 1876(1):188547. PMID: 33932561.
      View in: PubMed
    18. Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci AD, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy. 2021 Apr 28. PMID: 33906376.
      View in: PubMed
    19. Rizzo A, Mollica V, Dall'Olio FG, Ricci AD, Maggio I, Marchetti A, Rosellini M, Santoni M, Ardizzoni A, Massari F. Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. Future Oncol. 2021 Apr 21. PMID: 33880963.
      View in: PubMed
    20. Rizzo A, Mollica V, Rosellini M, Marchetti A, Ricci AD, Fiorentino M, Battelli N, Santoni M, Massari F. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. Pathol Res Pract. 2021 Apr 09; 222:153440. PMID: 33857854.
      View in: PubMed
    21. Rizzo A, Mollica V, Santoni M, Ricci AD, Rosellini M, Marchetti A, Montironi R, Ardizzoni A, Massari F. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. Eur Urol Focus. 2021 Mar 10. PMID: 33714725.
      View in: PubMed
    22. Mollica V, Rizzo A, Di Nunno V, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Cimadamore A, Montironi R, Massari F. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF? Transl Androl Urol. 2021 Mar; 10(3):1581-1587. PMID: 33850792.
      View in: PubMed
    23. Santoni M, Cimadamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R. Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. Transl Androl Urol. 2021 Mar; 10(3):1562-1568. PMID: 33850790.
      View in: PubMed
    24. Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Schiavina R, Cheng L, Lopez-Beltran A, Brunocilla E, Montironi R, Massari F. TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?-a narrative review. Transl Androl Urol. 2021 Mar; 10(3):1541-1552. PMID: 33850788.
      View in: PubMed
    25. Montironi R, Cheng L, Cimadamore A, Mazzucchelli R, Scarpelli M, Santoni M, Massari F, Lopez-Beltran A. Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups? Transl Androl Urol. 2021 Mar; 10(3):1530-1540. PMID: 33850787.
      View in: PubMed
    26. Cimadamore A, Cheng L, Scarpelli M, Massari F, Mollica V, Santoni M, Lopez-Beltran A, Montironi R, Moch H. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. Transl Androl Urol. 2021 Mar; 10(3):1506-1520. PMID: 33850785.
      View in: PubMed
    27. Aurilio G, Cimadamore A, Lopez-Beltran A, Scarpelli M, Massari F, Verri E, Cheng L, Santoni M, Montironi R. Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. Transl Androl Urol. 2021 Mar; 10(3):1521-1529. PMID: 33850786.
      View in: PubMed
    28. Santoni M, Miccini F, Cimadamore A, Piva F, Massari F, Cheng L, Lopez-Beltran A, Montironi R, Battelli N. An update on investigational therapies that target STAT3 for the treatment of cancer. Expert Opin Investig Drugs. 2021 Mar; 30(3):245-251. PMID: 33599169.
      View in: PubMed
    29. Massari F, Rizzo A, Mollica V, Santoni M. A brand-new CAR for macrophages: is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? Future Oncol. 2021 May; 17(15):1839-1841. PMID: 33590766.
      View in: PubMed
    30. Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. Treating Prostate Cancer by Antibody-Drug Conjugates. Int J Mol Sci. 2021 Feb 04; 22(4). PMID: 33557050.
      View in: PubMed
    31. Santoni M, Massari F, Santoni G, Cimadamore A, Montironi R, Battelli N. Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. Eur Urol. 2021 Feb 03. PMID: 33549360.
      View in: PubMed
    32. Mollica V, Rizzo A, Rosellini M, Marchetti A, Ricci AD, Cimadamore A, Scarpelli M, Bonucci C, Andrini E, Errani C, Santoni M, Montironi R, Massari F. Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers (Basel). 2021 Feb 01; 13(3). PMID: 33535541.
      View in: PubMed
    33. Rizzo A, Mollica V, Massari F. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. Eur Urol Focus. 2021 Jan 27. PMID: 33516645.
      View in: PubMed
    34. Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Rizzo M, Cartenì G, Grande E, Matrana MR, Crabb SJ, Vau N, Sorgentoni G, Cimadamore A, Montironi R, Battelli N. Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? Diagnostics (Basel). 2021 Jan 18; 11(1). PMID: 33477676.
      View in: PubMed
    35. Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, Cheng L, Montironi R. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers (Basel). 2021 Jan 03; 13(1). PMID: 33401585.
      View in: PubMed
    36. Mollica V, Rizzo A, Tassinari E, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anticancer Drugs. 2021 01 01; 32(1):74-81. PMID: 33290315.
      View in: PubMed
    37. Akamatsu Y, Gomez-Paz S, Vergara-Garcia D, Moholkar VM, Kuhn AL, Chida K, Singh J, Rodrigues KM, Massari F, Moore JM, Puri AS, Ogilvy CS, Thomas AJ. Role of Surgical Intervention for Intracranial Dural Arteriovenous Fistulas With Cortical Venous Drainage in an Endovascular Era: A Case Series. Oper Neurosurg (Hagerstown). 2020 Dec 30. PMID: 33378448.
      View in: PubMed
    38. Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells. 2020 Dec 10; 9(12). PMID: 33321757.
      View in: PubMed
    39. Santoni M, Piva F, Porta C, Bracarda S, Heng DY, Matrana MR, Grande E, Mollica V, Aurilio G, Rizzo M, Giulietti M, Montironi R, Massari F. Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clin Genitourin Cancer. 2020 Nov 10. PMID: 33262083.
      View in: PubMed
    40. Levy J, Hopkins T, Morris J, Tran ND, David E, Massari F, Farid H, Vogel A, O'Connell WG, Sunenshine P, Dixon R, Gangi A, von der Höh N, Bagla S. Radiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients. J Vasc Interv Radiol. 2020 Nov; 31(11):1745-1752. PMID: 33129427.
      View in: PubMed
    41. Zong Y, Montironi R, Massari F, Jiang Z, Lopez-Beltran A, Wheeler TM, Scarpelli M, Santoni M, Cimadamore A, Cheng L. Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. Eur Urol Focus. 2020 Oct 29. PMID: 33132109.
      View in: PubMed
    42. Kühn AL, Singh J, de Macedo Rodrigues K, Massari F, Moholkar VM, Marwah SK, Unar D, Gounis MJ, Puri AS. Distal radial artery (Snuffbox) access for intracranial aneurysm treatment using the Woven EndoBridge (WEB) device. J Clin Neurosci. 2020 Nov; 81:310-315. PMID: 33222936.
      View in: PubMed
    43. Cimadamore A, Cheng L, Scarpelli M, Lopez-Beltran A, Mollica V, Montironi R, Massari F. Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. Eur Urol. 2020 Oct 13. PMID: 33067017.
      View in: PubMed
    44. Santoni M, Massari F, Aurilio G, Mollica V, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Nolé F, Montironi R. Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy. 2020 Dec; 12(17):1257-1268. PMID: 32998603.
      View in: PubMed
    45. Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Target Oncol. 2020 Oct; 15(5):691. PMID: 32857328.
      View in: PubMed
    46. Kühn AL, Singh J, Moholkar VM, Satti SR, Rodrigues KM, Massari F, Gounis MJ, McGowen A, Puri AS. Distal radial artery (snuffbox) access for carotid artery stenting - Technical pearls and procedural set-up. Interv Neuroradiol. 2020 Sep 13; 1591019920959537. PMID: 32924692.
      View in: PubMed
    47. Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, Cheng L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F. Is There a Role for Immunotherapy in Prostate Cancer? Cells. 2020 Sep 08; 9(9). PMID: 32911806.
      View in: PubMed
    48. Loriot Y, Sternberg CN, Castellano D, Oosting SF, Dumez H, Huddart R, Vianna K, Alonso Gordoa T, Skoneczna I, Fay AP, Nolè F, Massari F, Brasiuniene B, Maroto P, Fear S, Di Nucci F, de Ducla S, Choy E. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. Eur J Cancer. 2020 Sep 06; 138:202-211. PMID: 32905959.
      View in: PubMed
    49. Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 Sep; 20(9):755-763. PMID: 32757789.
      View in: PubMed
    50. Iacovelli R, Ciccarese C, Facchini G, Milella M, Urbano F, Basso U, De Giorgi U, Sabbatini R, Santini D, Berardi R, Santoni M, Bracarda S, Massari F, Masini C, De Tursi M, Ricotta R, Buti S, Zustovich F, Sepe P, Rossetti S, Maruzzo M, Cortesi E, Tortora G, Procopio G. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Target Oncol. 2020 Aug; 15(4):495-501. PMID: 32671807.
      View in: PubMed
    51. Kuhn AL, Puri AS, De Macedo Rodrigues K, Massari F, Singh J. Trapped Embolic Protection Device: A Salvage Technique. Cureus. 2020 Jul 16; 12(7):e9228. PMID: 32821577.
      View in: PubMed
    52. Conteduca V, Caffo O, Scarpi E, Sepe P, Galli L, Fratino L, Maines F, Chiuri VE, Santoni M, Zanardi E, Massari F, Toma I, Lolli C, Schepisi G, Sbrana A, Kinspergher S, Cursano MC, Casadei C, Modonesi C, Santini D, Procopio G, De Giorgi U. Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. J Clin Med. 2020 Jun 22; 9(6). PMID: 32580478.
      View in: PubMed
    53. Aurilio G, Cimadamore A, Santoni M, Nolè F, Scarpelli M, Massari F, Lopez-Beltran A, Cheng L, Montironi R. New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? Cells. 2020 06 22; 9(6). PMID: 32580469.
      View in: PubMed
    54. Cimadamore A, Aurilio G, Nolé F, Massari F, Scarpelli M, Santoni M, Lopez-Beltran A, Cheng L, Montironi R. Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. Cells. 2020 06 19; 9(6). PMID: 32575429.
      View in: PubMed
    55. Santoni M, Massari F, Cheng L, Cimadamore A, Scarpelli M, Montironi R, Lopez-Beltran A. PD-L1 inhibitors for the treatment of prostate cancer. Curr Drug Targets. 2020 Jun 09. PMID: 32516098.
      View in: PubMed
    56. Mollica V, Rizzo A, Montironi R, Cheng L, Giunchi F, Schiavina R, Santoni M, Fiorentino M, Lopez-Beltran A, Brunocilla E, Brandi G, Massari F. Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers (Basel). 2020 Jun 02; 12(6). PMID: 32498352.
      View in: PubMed
    57. Donini M, Buti S, Massari F, Mollica V, Rizzo A, Montironi R, Bersanelli M, Santoni M. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. Expert Rev Anticancer Ther. 2020 Jun; 20(6):491-501. PMID: 32479120.
      View in: PubMed
    58. Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L. Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. Cells. 2020 04 25; 9(5). PMID: 32344931.
      View in: PubMed
    59. Cimadamore A, Massari F, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Moch H. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay. Curr Drug Targets. 2020 Mar 24. PMID: 32208115.
      View in: PubMed
    60. Cimadamore A, Scarpelli M, Massari F, Eckstein M, Gevaert T, Cheng L, Lopez-Beltran A, Montironi R. Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. Expert Opin Biol Ther. 2020 Jun; 20(6):539-544. PMID: 32081061.
      View in: PubMed
    61. Di Nunno V, Santoni M, Mollica V, Conti A, Montironi R, Battelli N, Ardizzoni A, Massari F. Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. Clin Drug Investig. 2020 Jan 28. PMID: 31993991.
      View in: PubMed
    62. Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R. Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. Future Oncol. 2020 Feb; 16(5):75-80. PMID: 31916449.
      View in: PubMed
    63. Kühn AL, de Macedo Rodrigues K, Singh J, Massari F, Puri AS. Distal radial access in the anatomical snuffbox for neurointerventions: a feasibility, safety, and proof-of-concept study. J Neurointerv Surg. 2020 Jan 08. PMID: 31915209.
      View in: PubMed
    64. Mollica V, Santoni M, Di Nunno V, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Montironi R, Massari F. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. Curr Drug Targets. 2020; 21(14):1463-1475. PMID: 32160846.
      View in: PubMed
    65. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers (Basel). 2019 Dec 30; 12(1). PMID: 31905816.
      View in: PubMed
    66. Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Montironi R. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Rev Cardiovasc Ther. 2019 Dec; 17(12):917-927. PMID: 31829045.
      View in: PubMed
    67. Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R. Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. Expert Rev Mol Diagn. 2020 02; 20(2):231-243. PMID: 31795775.
      View in: PubMed
    68. Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy. 2019 12; 11(17):1507-1521. PMID: 31663411.
      View in: PubMed
    69. Mollica V, Di Nunno V, Santoni M, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Mariani C, Battelli N, Montironi R, Massari F. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. Expert Rev Mol Diagn. 2020 02; 20(2):207-217. PMID: 31640441.
      View in: PubMed
    70. Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L. Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Rev Mol Diagn. 2020 02; 20(2):255-264. PMID: 31608720.
      View in: PubMed
    71. Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Caliò A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F. A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. Mol Diagn Ther. 2019 10; 23(5):569-577. PMID: 31332726.
      View in: PubMed
    72. Cimadamore A, Scarpelli M, Raspollini MR, Doria A, Galosi AB, Massari F, Di Nunno V, Cheng L, Lopez-Beltran A, Montironi R. Prostate cancer pathology: What has changed in the last 5 years. Urologia. 2020 Feb; 87(1):3-10. PMID: 31545701.
      View in: PubMed
    73. Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, Moch H. Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. Expert Rev Mol Diagn. 2020 02; 20(2):141-150. PMID: 31498685.
      View in: PubMed
    74. Cimadamore A, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Liquid biopsies in renal cell carcinoma with focus on epigenome analysis. Ann Transl Med. 2019 Sep; 7(Suppl 6):S194. PMID: 31656773.
      View in: PubMed
    75. Santoni M, Cimadamore A, Massari F, Piva F, Aurilio G, Martignetti A, Scarpelli M, Di Nunno V, Gatto L, Battelli N, Cheng L, Lopez-Beltran A, Montironi R. Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. Cancers (Basel). 2019 Aug 22; 11(9). PMID: 31443386.
      View in: PubMed
    76. Di Nunno V, Mollica V, Schiavina R, Nobili E, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2020 04; 18(2):e83-e90. PMID: 31753738.
      View in: PubMed
    77. Massari F, Di Nunno V, Santoni M, Gatto L, Caserta C, Morelli F, Zafarana E, Carrozza F, Mosca A, Mollica V, Iacovelli R, Sabbatini R, Porta C, Bracarda S. Toward a genome-based treatment landscape for renal cell carcinoma. Crit Rev Oncol Hematol. 2019 Oct; 142:141-152. PMID: 31401421.
      View in: PubMed
    78. Di Nunno V, Mollica V, Santoni M, Gatto L, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F. New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. Clin Genitourin Cancer. 2019 10; 17(5):e871-e877. PMID: 31378578.
      View in: PubMed
    79. Di Nunno V, Massari F, Mollica V, Cimadamore A, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. Ann Transl Med. 2019 Jul; 7(Suppl 3):S137. PMID: 31576344.
      View in: PubMed
    80. Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Massari F. Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers (Basel). 2019 Jun 14; 11(6). PMID: 31207938.
      View in: PubMed
    81. Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, Battelli N, Brandi G, Massari F. BAP1 in solid tumors. Future Oncol. 2019 Jun; 15(18):2151-2162. PMID: 31159579.
      View in: PubMed
    82. Mollica V, Di Nunno V, Gatto L, Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F. Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. Clin Drug Investig. 2019 Jun; 39(6):503-519. PMID: 30937824.
      View in: PubMed
    83. Nunno VD, Mollica V, Gatto L, Santoni M, Cosmai L, Porta C, Massari F. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy. 2019 05; 11(7):631-643. PMID: 30943858.
      View in: PubMed
    84. Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R. Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. Front Oncol. 2019; 9:228. PMID: 31024837.
      View in: PubMed
    85. Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Brandi G. The Human Microbiota and Prostate Cancer: Friend or Foe? Cancers (Basel). 2019 Mar 31; 11(4). PMID: 30935126.
      View in: PubMed
    86. Cimadamore A, Santoni M, Massari F, Gasparrini S, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M. Microbiome and Cancers, With Focus on Genitourinary Tumors. Front Oncol. 2019; 9:178. PMID: 30972292.
      View in: PubMed
    87. Di Nunno V, Santoni M, Gatto L, Mollica V, Massari F. Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353-66: Metastatic Hormone-naïve Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease. Eur Urol Oncol. 2020 06; 3(3):390. PMID: 31411989.
      View in: PubMed
    88. Santoni M, Maiorani G, Faloppi L, Di Nunno V, Gatto L, Massari F, Battelli N. Optimizing renal function and outcome of patients with cT2 renal cell carcinoma. Ann Transl Med. 2019 Mar; 7(Suppl 1):S39. PMID: 31032318.
      View in: PubMed
    89. Di Nunno V, Mollica V, Gatto L, Santoni M, Sorgentoni G, Battelli N, Massari F. Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? Ann Transl Med. 2019 Mar; 7(Suppl 1):S38. PMID: 31032317.
      View in: PubMed
    90. Cimadamore A, Gasparrini S, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. Cancers (Basel). 2019 Feb 07; 11(2). PMID: 30736478.
      View in: PubMed
    91. Massari F, Di Nunno V, Santoni M, Gatto L, Mollica V, Porta C. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. Eur Urol Oncol. 2019 09; 2(5):603-604. PMID: 31411982.
      View in: PubMed
    92. Mollica V, Di Nunno V, Cimadamore A, Lopez-Beltran A, Cheng L, Santoni M, Scarpelli M, Montironi R, Massari F. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells. 2019 01 11; 8(1). PMID: 30642011.
      View in: PubMed
    93. Cimadamore A, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. Curr Drug Metab. 2019; 20(4):305-312. PMID: 30799789.
      View in: PubMed
    94. Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, Galosi AB, Scarpelli M, Montironi R. New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. Front Oncol. 2018; 8:653. PMID: 30622933.
      View in: PubMed
    95. Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, Brunocilla E, Ardizzoni A, Porta C. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Target Oncol. 2018 12; 13(6):705-714. PMID: 30324488.
      View in: PubMed
    96. Saeed O, Lopez-Beltran A, Fisher KW, Scarpelli M, Montironi R, Cimadamore A, Massari F, Santoni M, Cheng L. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. J Clin Pathol. 2019 Feb; 72(2):135-139. PMID: 30425122.
      View in: PubMed
    97. Di Nunno V, Gatto L, Fragomeno B, Cubelli M, Nobili E, Romano I, Santoni M, Pisconti S, Montironi R, Massari F. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back? Future Oncol. 2018 Dec; 14(29):2997-2999. PMID: 30411632.
      View in: PubMed
    98. Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The Identification of Immunological Biomarkers in Kidney Cancers. Front Oncol. 2018; 8:456. PMID: 30450335.
      View in: PubMed
    99. Santoni M, Montironi R, Battelli N, Massari F. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma. Eur Urol. 2019 03; 75(3):e64-e66. PMID: 30391082.
      View in: PubMed
    100. Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. Immunotherapy. 2018 10; 10(14):1229-1239. PMID: 30326787.
      View in: PubMed
    101. Di Nunno V, Gatto L, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Massari F. Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Front Oncol. 2018; 8:397. PMID: 30319966.
      View in: PubMed
    102. Di Nunno V, Santoni M, Massari F. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival? Eur Urol Oncol. 2019 07; 2(4):471. PMID: 31277785.
      View in: PubMed
    103. Di Nunno V, Santoni M, Massari F. Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? Lancet Oncol. 2018 09; 19(9):e437. PMID: 30191844.
      View in: PubMed
    104. Di Nunno V, Cimadamore A, Santoni M, Scarpelli M, Fiorentino M, Ciccarese C, Iacovelli R, Cheng L, Lopez-Beltran A, Massari F, Montironi R. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncol. 2018 Oct; 14(25):2559-2564. PMID: 30141348.
      View in: PubMed
    105. Massari F, Di Nunno V, Santoni M. Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma? Eur Urol Oncol. 2019 05; 2(3):340-341. PMID: 31200852.
      View in: PubMed
    106. Di Nunno V, Santoni M, Cimadamore A, Battelli N, Massari F. Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: Are We Ready for the Next Step? Eur Urol. 2018 11; 74(5):e118-e119. PMID: 30017397.
      View in: PubMed
    107. Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Rev Mol Diagn. 2018 07; 18(7):645-655. PMID: 29912582.
      View in: PubMed
    108. Massari F, Santoni M, di Nunno V, Cheng L, Lopez-Beltran A, Cimadamore A, Gasparrini S, Scarpelli M, Battelli N, Montironi R. Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treat Rev. 2018 Jul; 68:80-85. PMID: 29886353.
      View in: PubMed
    109. Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018; 7:212528. PMID: 29899754.
      View in: PubMed
    110. Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N. Tivozanib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2018 Jun; 19(9):1021-1025. PMID: 29851529.
      View in: PubMed
    111. Mosillo C, Ciccarese C, Bimbatti D, Fantinel E, Volta AD, Bisogno I, Zampiva I, Santoni M, Massari F, Brunelli M, Montironi R, Tortora G, Iacovelli R. Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research. Cancer Treat Rev. 2018 Jun; 67:29-33. PMID: 29753244.
      View in: PubMed
    112. Montironi R, Cimadamore A, Gasparrini S, Mazzucchelli R, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. Expert Rev Anticancer Ther. 2018 07; 18(7):685-693. PMID: 29699428.
      View in: PubMed
    113. Di Nunno V, Santoni M, Massari F. Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15. Eur Urol. 2018 08; 74(2):e50. PMID: 29709313.
      View in: PubMed
    114. Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clin Genitourin Cancer. 2018 08; 16(4):e945-e951. PMID: 29753637.
      View in: PubMed
    115. Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev. 2018 Mar; 64:11-20. PMID: 29407369.
      View in: PubMed
    116. Massari F, Di Nunno V, Comito F, Cubelli M, Ciccarese C, Iacovelli R, Fiorentino M, Montironi R, Ardizzoni A. Circulating tumor cells in genitourinary tumors. Ther Adv Urol. 2018 Feb; 10(2):65-77. PMID: 29434674.
      View in: PubMed
    117. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018 01; 31(1):24-38. PMID: 29148538.
      View in: PubMed
    118. Montironi R, Cimadamore A, Massari F, Montironi MA, Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M. Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. Arch Pathol Lab Med. 2017 11; 141(11):1460-1461. PMID: 29072947.
      View in: PubMed
    119. Mann SA, Lopez-Beltran A, Massari F, Pili R, Fiorentino M, Koch MO, Kaimakliotis HZ, Wang L, Scarpelli M, Ciccarese C, Moch H, Montironi R, Cheng L. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. Curr Drug Metab. 2017 Oct 16; 18(8):700-711. PMID: 28524003.
      View in: PubMed
    120. Blanca A, Cheng L, Montironi R, Moch H, Massari F, Fiorentino M, Raspollini MR, Scarpelli M, Lopez-Beltran A. Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. Curr Drug Metab. 2017 Oct 16; 18(8):712-722. PMID: 28524002.
      View in: PubMed
    121. Giunchi F, Ciccarese C, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Moch H, Massari F, Fiorentino M. Urinary Biomarkers for Prostate Cancer. Curr Drug Metab. 2017 Oct 16; 18(8):723-726. PMID: 28524004.
      View in: PubMed
    122. Gasparrini S, Cimadamore A, Scarpelli M, Massari F, Doria A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montironi R. Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian J Androl. 2017 Aug 04. PMID: 28782737.
      View in: PubMed
    123. Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R. Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Rev Mol Diagn. 2017 08; 17(8):781-789. PMID: 28598696.
      View in: PubMed
    124. Montironi R, Gasparrini S, Lopez-Beltran A, Cheng L, Massari F, Montorsi F, Scarpelli M. Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol 2017;71:790-807. Eur Urol. 2017 11; 72(5):e139-e141. PMID: 28576502.
      View in: PubMed
    125. Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urol Oncol. 2017 09; 35(9):541.e7-541.e13. PMID: 28572027.
      View in: PubMed
    126. De Macedo Rodrigues K, Kühn AL, Tamura T, Dabus G, Kan P, Marosfoi MG, Lozano JD, Perras M, Brooks C, Howk MC, Hou SY, Rex DE, Massari F, Gounis MJ, Wakhloo AK, Puri AS. Pipeline Embolization Device for Pericallosal Artery Aneurysms: A Retrospective Single Center Safety and Efficacy Study. Oper Neurosurg (Hagerstown). 2017 May 17. PMID: 28521024.
      View in: PubMed
    127. Montironi R, Lopez-Beltran A, Cheng L, Gasparrini S, Montironi MA, Massari F, Scarpelli M, Montorsi F. Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. Eur Urol 2017;71:e73-5. Eur Urol. 2017 08; 72(2):e37-e38. PMID: 28292549.
      View in: PubMed
    128. Ciccarese C, Massari F, Blanca A, Tortora G, Montironi R, Cheng L, Scarpelli M, Raspollini MR, Vau N, Fonseca J, Lopez-Beltran A. Tp53 and its potential therapeutic role as a target in bladder cancer. Expert Opin Ther Targets. 2017 Apr; 21(4):401-414. PMID: 28281901.
      View in: PubMed
    129. Ciccarese C, Massari F, Iacovelli R, Fiorentino M, Montironi R, Di Nunno V, Giunchi F, Brunelli M, Tortora G. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treat Rev. 2017 Mar; 54:68-73. PMID: 28231559.
      View in: PubMed
    130. Cimadamore A, Scarpelli M, Piva F, Massari F, Gasparrini S, Doria A, Cheng L, Lopez-Beltran A, Montironi R. Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. Future Oncol. 2017 May; 13(12):1105-1114. PMID: 28147707.
      View in: PubMed
    131. Fiorentino M, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C, Bimbatti D, Scarpa A, Iacovelli R, Porta C, Virinder S, Tortora G, Artibani W, Schiavina R, Ardizzoni A, Brunelli M, Knuutila S, Martignoni G. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget. 2017 Jan 31; 8(5):7328-7335. PMID: 27741505.
      View in: PubMed
    132. Cimadamore A, Gasparrini S, Scarpelli M, Doria A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montironi R. Epigenetic Modifications and Modulators in Prostate Cancer. Crit Rev Oncog. 2017; 22(5-6):439-450. PMID: 29604923.
      View in: PubMed
    133. Massari F, Ciccarese C, Bria E, Porta C, La Russa F, Knuutila S, Artibani W, Porcaro AB, Bimbatti D, Modena A, Sava T, Tortora G, Cheng L, Eccher A, Cima L, Pedron S, Ghimenton C, Martignoni G, Brunelli M. Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. Appl Immunohistochem Mol Morphol. 2017 01; 25(1):39-43. PMID: 26509904.
      View in: PubMed
    134. Ciccarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F. Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? Curr Drug Metab. 2017; 18(8):692-699. PMID: 28524006.
      View in: PubMed
    135. Kühn AL, Wakhloo AK, Gounis MJ, Kan P, de Macedo Rodrigues K, Lozano JD, Marosfoi MG, Perras M, Brooks C, Howk MC, Rex DE, Massari F, Puri AS. Use of self-expanding stents for better intracranial flow diverter wall apposition. Interv Neuroradiol. 2016 Dec 12. PMID: 27956518.
      View in: PubMed
    136. Kühn AL, de Macedo Rodrigues K, Lozano JD, Rex DE, Massari F, Tamura T, Howk M, Brooks C, L'Heureux J, Gounis MJ, Wakhloo AK, Puri AS. Use of the Pipeline embolization device for recurrent and residual cerebral aneurysms: a safety and efficacy analysis with short-term follow-up. J Neurointerv Surg. 2016 Nov 25. PMID: 27888225.
      View in: PubMed
    137. Gasparrini S, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Lopez-Beltran A, Cheng L, Montironi R. Prostate cancer grading in 2016. Minerva Urol Nefrol. 2017 02; 69(1):1-4. PMID: 27813397.
      View in: PubMed
    138. Montironi R, Gasparrini S, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montorsi F, Scarpelli M. Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. Eur Urol. 2017 02; 71(2):e73-e75. PMID: 27568062.
      View in: PubMed
    139. Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, Crabb SJ, Massari F, Aieta M, Conteduca V, Maruzzo M, La Russa F, Wheater M, Berardi R, Galli L, De Giorgi U. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget. 2016 08 23; 7(34):54564-54571. PMID: 27409344.
      View in: PubMed
    140. Modena A, Massari F, Ciccarese C, Brunelli M, Santoni M, Montironi R, Martignoni G, Tortora G. Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? Target Oncol. 2016 08; 11(4):431-46. PMID: 26846650.
      View in: PubMed
    141. Schepisi G, Santoni M, Massari F, Gurioli G, Salvi S, Conteduca V, Montironi R, De Giorgi U. Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. BioDrugs. 2016 Aug; 30(4):263-73. PMID: 27177757.
      View in: PubMed
    142. Ciccarese C, Brunelli M, Montironi R, Fiorentino M, Iacovelli R, Heng D, Tortora G, Massari F. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016 Sep; 49:37-44. PMID: 27453294.
      View in: PubMed
    143. Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Raspollini MR, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Genitourinary cancers: molecular determinants for personalized therapies. Urologia. 2016 Sep 26; 83(3):107-109. PMID: 27338983.
      View in: PubMed
    144. Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer. Future Oncol. 2016 Sep; 12(17):1971-4. PMID: 27312584.
      View in: PubMed
    145. Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer. Future Oncol. 2016 Sep; 12(17):1967-70. PMID: 27312426.
      View in: PubMed
    146. Kühn AL, Wakhloo AK, Lozano JD, Massari F, De Macedo Rodrigues K, Marosfoi MG, Perras M, Brooks C, Howk M, Rex DE, Gounis MJ, Puri AS. Two-year single-center experience with the 'Baby Trevo' stent retriever for mechanical thrombectomy in acute ischemic stroke. J Neurointerv Surg. 2016 Jun 9. PMID: 27286991.
      View in: PubMed
    147. Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget. 2016 May 31; 7(22):33381-90. PMID: 27027342.
      View in: PubMed
    148. Lozano JD, Massari F, Howk MC, de Macedo Rodrigues K, Brooks C, Perras M, Rex DE, Wakhloo AK, Kühn AL, Puri AS. Utilization of a New Intracranial Support Catheter as an Intermediate Aspiration Catheter in the Treatment of Acute Ischemic Stroke: Technical Report on Initial Experience. Cureus. 2016; 8(5):e617. PMID: 27382525.
      View in: PubMed
    149. Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Ciccarese C, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. Immunotargeting and personalized therapies in genitourinary cancers. Future Oncol. 2016 Aug; 12(16):1853-6. PMID: 27113700.
      View in: PubMed
    150. Modena A, Ciccarese C, Iacovelli R, Brunelli M, Montironi R, Fiorentino M, Tortora G, Massari F. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev. 2016 Apr 15; 10(1):293. PMID: 27471580.
      View in: PubMed
    151. Minardi D, Mazzucchelli R, Scarpelli M, Massari F, Ciccarese C, Lopez-Beltran A, Cheng L, Montironi R. Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3. Future Oncol. 2016 Jun; 12(12):1431-3. PMID: 27189718.
      View in: PubMed
    152. Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R. Metabolic phenotype of bladder cancer. Cancer Treat Rev. 2016 Apr; 45:46-57. PMID: 26975021.
      View in: PubMed
    153. Massari F, Henninger N, Lozano JD, Patel A, Kuhn AL, Howk M, Perras M, Brooks C, Gounis MJ, Kan P, Wakhloo AK, Puri AS. ARTS (Aspiration-Retriever Technique for Stroke): Initial clinical experience. Interv Neuroradiol. 2016 Jun; 22(3):325-32. PMID: 26908591.
      View in: PubMed
    154. Ciccarese C, Santoni M, Massari F. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. N Engl J Med. 2016 01 21; 374(3):286. PMID: 26789884.
      View in: PubMed
    155. Montironi R, Santoni M, Massari F, Lopez-Beltran A, Cheng L, Berardi R, Scarpelli M. Editorial: Emerging Immunotargets in Genitourinary Tumors. Curr Drug Targets. 2016; 17(7):748-9. PMID: 27086839.
      View in: PubMed
    156. Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M. Emerging Immunotargets and Immunotherapies in Prostate Cancer. Curr Drug Targets. 2016; 17(7):777-82. PMID: 26898309.
      View in: PubMed
    157. Ciccarese C, Santoni M, Massari F, Modena A, Piva F, Conti A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Tortora G, Montironi R. Metabolic Alterations in Renal and Prostate Cancer. Curr Drug Metab. 2016; 17(2):150-5. PMID: 26467063.
      View in: PubMed
    158. Kucharczyk J, Matrana MR, Santoni M, Massari F, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S, Montironi R, Holger M. Emerging Immunotargets in Metastatic Renal Cell Carcinoma. Curr Drug Targets. 2016; 17(7):771-6. PMID: 26648075.
      View in: PubMed
    159. Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. An Overview of Emerging Immunotargets of Genitourinary Tumors. Curr Drug Targets. 2016; 17(7):750-6. PMID: 26648079.
      View in: PubMed
    160. Massari F, Ciccarese C, Vau N, Santoni M, Montironi R, Cheng L, Marques RC, Scarpelli M, Fonseca J, Matrana MR, Holger M, Cascinu S, Tortora G, Lopez-Beltran A. Emerging Immunotargets in Bladder Cancer. Curr Drug Targets. 2016; 17(7):757-70. PMID: 26844572.
      View in: PubMed
    161. Puri AS, Massari F, Asai T, Marosfoi M, Kan P, Hou SY, Howk M, Perras M, Brooks C, Clarencon F, Gounis MJ, Wakhloo AK. Safety, efficacy, and short-term follow-up of the use of Pipeline Embolization Device in small (<2.5 mm) cerebral vessels for aneurysm treatment: single institution experience. Neuroradiology. 2016 Mar; 58(3):267-75. PMID: 26700827.
      View in: PubMed
    162. Ciccarese C, Santoni M, Brunelli M, Buti S, Modena A, Nabissi M, Artibani W, Martignoni G, Montironi R, Tortora G, Massari F. AR-V7 and prostate cancer: The watershed for treatment selection? Cancer Treat Rev. 2016 Feb; 43:27-35. PMID: 26827690.
      View in: PubMed
    163. Santoni M, Piva F, Scarpelli M, Cheng L, Lopez-Beltran A, Massari F, Iacovelli R, Berardi R, Santini D, Montironi R. The origin of prostate metastases: emerging insights. Cancer Metastasis Rev. 2015 Dec; 34(4):765-73. PMID: 26363603.
      View in: PubMed
    164. Massari F, Ciccarese C, Santoni M, Lopez-Beltran A, Scarpelli M, Montironi R, Cheng L. Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Rev Anticancer Ther. 2015; 15(12):1367-9. PMID: 26568023.
      View in: PubMed
    165. Kühn AL, Kan P, Massari F, Lozano JD, Hou SY, Howk M, Gounis MJ, Wakhloo AK, Puri AS. Endovascular reconstruction of unruptured intradural vertebral artery dissecting aneurysms with the Pipeline embolization device. J Neurointerv Surg. 2016 Oct; 8(10):1048-51. PMID: 26546600.
      View in: PubMed
    166. Santoni M, Conti A, Piva F, Massari F, Ciccarese C, Burattini L, Cheng L, Lopez-Beltran A, Scarpelli M, Santini D, Tortora G, Cascinu S, Montironi R. Role of STAT3 pathway in genitourinary tumors. Future Sci OA. 2015 Nov; 1(3):FSO15. PMID: 28031890.
      View in: PubMed
    167. Piva F, Giulietti M, Occhipinti G, Santoni M, Massari F, Sotte V, Iacovelli R, Burattini L, Santini D, Montironi R, Cascinu S, Principato G. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget. 2015 Oct 13; 6(31):32161-8. PMID: 26452128.
      View in: PubMed
    168. Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn. 2015; 15(9):1201-10. PMID: 26166446.
      View in: PubMed
    169. Massari F, Ciccarese C, Santoni M, Brunelli M, Piva F, Modena A, Bimbatti D, Fantinel E, Santini D, Cheng L, Cascinu S, Montironi R, Tortora G. Metabolic alterations in renal cell carcinoma. Cancer Treat Rev. 2015 Nov; 41(9):767-76. PMID: 26169313.
      View in: PubMed
    170. Massari F, Santoni M, Ciccarese C, Santini D. The immunocheckpoints in modern oncology: the next 15 years. Expert Opin Biol Ther. 2015 Jul; 15(7):917-21. PMID: 26063384.
      View in: PubMed
    171. Iacovelli R, Santini D, Rizzo M, Felici A, Santoni M, Verzoni E, Masini C, Massari F, Calvani N, Mosca A, Procopio G. Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Can Urol Assoc J. 2015 Jul-Aug; 9(7-8):263-7. PMID: 26316911.
      View in: PubMed
    172. Santoni M, Conti A, Andrikou K, Bittoni A, Lanese A, Pistelli M, Pantano F, Vincenzi B, Armento G, Massari F, Tonini G, Cascinu S, Santini D. Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. Crit Rev Oncol Hematol. 2015 Nov; 96(2):206-19. PMID: 26070625.
      View in: PubMed
    173. Massari F, Bria E, Ciccarese C, Munari E, Modena A, Zambonin V, Sperduti I, Artibani W, Cheng L, Martignoni G, Tortora G, Brunelli M. Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. PLoS One. 2015; 10(6):e0127908. PMID: 26046361.
      View in: PubMed
    174. Ciccarese C, Massari F, Santoni M, Heng DY, Sotte V, Brunelli M, Conti A, Cheng L, Lopez-Beltran A, Scarpelli M, Cascinu S, Tortora G, Montironi R. New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treat Rev. 2015 Jul; 41(7):614-22. PMID: 26036356.
      View in: PubMed
    175. Massari F, Santoni M, Ciccarese C, Brunelli M, Conti A, Santini D, Montironi R, Cascinu S, Tortora G. Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Crit Rev Oncol Hematol. 2015 Oct; 96(1):81-90. PMID: 26022449.
      View in: PubMed
    176. Puri AS, Gounis MJ, Massari F, Howk M, Weaver J, Wakhloo AK. Monotherapy with stenting in subarachnoid hemorrhage (SAH) after middle cerebral artery dissection. J Neurointerv Surg. 2016 Apr; 8(4):e13. PMID: 25854687.
      View in: PubMed
    177. Puri AS, Massari F, Hou SY, Lozano JD, Howk M, Perras M, Brooks C, Gounis MJ, Kan P, Wakhloo AK. Onyx embolization in distal dissecting posterior inferior cerebellar artery aneurysms. J Neurointerv Surg. 2016 May; 8(5):501-6. PMID: 25838199.
      View in: PubMed
    178. Puri AS, Gounis MJ, Massari F, Howk M, Weaver J, Wakhloo AK. Monotherapy with stenting in subarachnoid hemorrhage (SAH) after middle cerebral artery dissection. BMJ Case Rep. 2015 Apr 01; 2015. PMID: 25833904.
      View in: PubMed
    179. Santoni M, Massari F, Del Re M, Ciccarese C, Piva F, Principato G, Montironi R, Santini D, Danesi R, Tortora G, Cascinu S. Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jun; 24(6):809-24. PMID: 25746129.
      View in: PubMed
    180. Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, Santini D. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J Exp Clin Cancer Res. 2015 Feb 05; 34:10. PMID: 25651794; PMCID: PMC4328067.
    181. Massari F, Ciccarese C, Santoni M, Brunelli M, Conti A, Modena A, Montironi R, Santini D, Cheng L, Martignoni G, Cascinu S, Tortora G. The route to personalized medicine in bladder cancer: where do we stand? Target Oncol. 2015 Sep; 10(3):325-36. PMID: 25634607.
      View in: PubMed
    182. Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015 Dec; 10(4):517-22. PMID: 25559290.
      View in: PubMed
    183. Ciccarese C, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Conti A, Tortora G, Cascinu S, Montironi R. Present and future of personalized medicine in adult genitourinary tumors. Future Oncol. 2015; 11(9):1381-8. PMID: 25952784.
      View in: PubMed
    184. Lopez-Beltran A, Santoni M, Massari F, Ciccarese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C, Montironi R. Bladder cancer: molecular determinants of personalized therapy. Curr Drug Targets. 2015; 16(2):115-24. PMID: 25654736.
      View in: PubMed
    185. Santoni M, Massari F, Iacovelli R, Ciccarese C, Verri E, Burattini L, Montironi R, Nolè F, Tortora G, Cascinu S. Inside the 2015 ASCO Genitourinary Cancers Symposium. Future Oncol. 2015; 11(13):1859-62. PMID: 26161923.
      View in: PubMed
    186. Buti S, Ciccarese C, Zanoni D, Santoni M, Modena A, Maines F, Gilli A, Bria E, Brunelli M, Rimanti A, Cascinu S, Ardizzoni A, Tortora G, Massari F. Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand? Future Oncol. 2015; 11(1):107-19. PMID: 25572786.
      View in: PubMed
    187. Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol. 2015; 22(6):2094-100. PMID: 25472645.
      View in: PubMed
    188. Iacovelli R, Farcomeni A, Sternberg CN, Cartenì G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, Verzoni E, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Maria Ruggeri E, Berruti A, Procopio G. Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. J Urol. 2015 Jun; 193(6):1905-10. PMID: 25433306.
      View in: PubMed
    189. Bianconi M, Santoni M, Massari F, Faloppi L, Del Prete M, Giampieri R, Ciccarese C, Modena A, Tortora G, Scartozzi M, Cascinu S. Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice. Future Oncol. 2014 Nov; 10(14):2103-6. PMID: 25471023.
      View in: PubMed
    190. Cianfoni A, Massari F, Ewing S, Persenaire M, Rumboldt Z, Bonaldi G. Combining percutaneous pedicular and extrapedicular access for tumor ablation in a thoracic vertebral body. Interv Neuroradiol. 2014 Oct 31; 20(5):603-8. PMID: 25363263.
      View in: PubMed
    191. Caffo O, De Giorgi U, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Macrini S, Messina C, Giordano M, Alesini D, Zustovich F, Fraccon AP, Vicario G, Conteduca V, Maines F, Galligioni E. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. BJU Int. 2015 May; 115(5):764-71. PMID: 24988879.
      View in: PubMed
    192. Massari F, Ciccarese C, Porcaro AB, Ferrero S, Gazzano G, Artibani W, Modena A, Bria E, Sava T, Caliò A, Novara G, Ficarra V, Chilosi M, Martignoni G, Bosari S, Cheng L, Tortora G, Brunelli M. Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. Pathology. 2014 Oct; 46(6):523-6. PMID: 25188333.
      View in: PubMed
    193. Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J Urol. 2015 Jan; 193(1):41-7. PMID: 25046616.
      View in: PubMed
    194. Santoni M, Massari F, Cascinu S. Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. Cell Mol Immunol. 2015 Jan; 12(1):122-4. PMID: 24882385.
      View in: PubMed
    195. Santoni M, Bracarda S, Nabissi M, Massari F, Conti A, Bria E, Tortora G, Santoni G, Cascinu S. CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. Biomed Res Int. 2014; 2014:768758. PMID: 24971349.
      View in: PubMed
    196. Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer Metastasis Rev. 2014 Mar; 33(1):321-31. PMID: 24337954.
      View in: PubMed
    197. Santoni M, Conti A, Massari F, Arnaldi G, Iacovelli R, Rizzo M, De Giorgi U, Trementino L, Procopio G, Tortora G, Cascinu S. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer. 2015 Jan 01; 136(1):1-10. PMID: 24415642.
      View in: PubMed
    198. Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2013 Dec; 62(12):1757-68. PMID: 24132754.
      View in: PubMed
    199. Iacovelli R, Cartenì G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Cerbone L, Procopio G. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer. 2013 Jun; 49(9):2134-42. PMID: 23518211.
      View in: PubMed
    200. Gandini R, Chiaravalloti A, Pampana E, Massari F, Morosetti D, Spano S, Loreni G, Simonetti G. Intracranial atheromatous disease treatment with the Wingspan stent system: evaluation of clinical, procedural outcome and restenosis rate in a single-center series of 21 consecutive patients with acute and mid-term results. Clin Neurol Neurosurg. 2013 Jun; 115(6):741-7. PMID: 22989778.
      View in: PubMed
    201. Speziale G, Nasso G, Piancone F, Generali K, Paterno C, Miccoli A, Fiore F, Del Prete A, Del Prete G, Lopriore V, Spirito F, Caldarola P, Paparella D, Massari F, Tavazzi L. One-year results after implantation of the CorCap for dilated cardiomyopathy and heart failure. Ann Thorac Surg. 2011 May; 91(5):1356-62. PMID: 21524444.
      View in: PubMed
    202. Masala S, Mammucari M, Angelopoulos G, Fiori R, Massari F, Faria S, Simonetti G. Percutaneous vertebroplasty in the management of vertebral osteoporotic fractures. Short-term, mid-term and long-term follow-up of 285 patients. Skeletal Radiol. 2009 Sep; 38(9):863-9. PMID: 19434408.
      View in: PubMed
    203. Masala S, Mastrangeli R, Petrella MC, Massari F, Ursone A, Simonetti G. Percutaneous vertebroplasty in 1,253 levels: results and long-term effectiveness in a single centre. Eur Radiol. 2009 Jan; 19(1):165-71. PMID: 18704433.
      View in: PubMed
    204. Masala S, Anselmetti GC, Marcia S, Massari F, Manca A, Simonetti G. Percutaneous vertebroplasty in multiple myeloma vertebral involvement. J Spinal Disord Tech. 2008 Jul; 21(5):344-8. PMID: 18600145.
      View in: PubMed
    205. Masala S, Pipitone V, Tomassini M, Massari F, Romagnoli A, Simonetti G. Percutaneous vertebroplasty in painful schmorl nodes. Cardiovasc Intervent Radiol. 2006 Jan-Feb; 29(1):97-101. PMID: 16328689.
      View in: PubMed
    206. Masala S, Schillaci O, Massari F, Danieli R, Ursone A, Fiori R, Simonetti G. MRI and bone scan imaging in the preoperative evaluation of painful vertebral fractures treated with vertebroplasty and kyphoplasty. In Vivo. 2005 Nov-Dec; 19(6):1055-60. PMID: 16277022.
      View in: PubMed
    207. Masala S, Fiori R, Massari F, Simonetti G. Kyphoplasty: indications, contraindications and technique. Radiol Med. 2005 Jul-Aug; 110(1-2):97-105. PMID: 16163144.
      View in: PubMed
    208. Pitzalis MV, Iacoviello M, Romito R, Massari F, Rizzon B, Luzzi G, Guida P, Andriani A, Mastropasqua F, Rizzon P. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol. 2002 Nov 06; 40(9):1615-22. PMID: 12427414.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Massari's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _